Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis
Francesco Schettini(Target (United States)), Daniele Generali(University of Trieste), Fabiola Giudici(University of Padua), G Grazia(Breast Cancer Research Foundation), Sabrina Nucera(University of Catania), Massimo Cristofanilli(Breast Cancer Care), Grazia Arpino(University of Naples Federico II), Paolo Vigneri(Humanitas University), Tomás Pascual(Breast Cancer Research Foundation), Alessandra Gennari(Ente Ospedaliero Ospedali Galliera), Rodrigo Sánchez-Bayona(Hospital Universitario 12 De Octubre), Benedetta Conte(Ospedale Policlinico San Martino), Mario Giuliano(Regione Campania), Richard Tancredi(Istituti Ospitalieri di Cremona), Carla Strina(Istituti Ospitalieri di Cremona), Lucia Del Mastro(Ospedale Policlinico San Martino), Matteo Lambertini(Ospedale Policlinico San Martino), Hope S. Rugo(UCSF Helen Diller Family Comprehensive Cancer Center), Carmen Criscitiello(University of Milan), Manuela Milani(Istituti Ospitalieri di Cremona), Giuseppe Curigliano(University of Milan)
Cited by 1
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k